KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Change in Accured Expenses (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Change in Accured Expenses for 8 consecutive years, with $12.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 100.41% year-over-year to $12.7 million, compared with a TTM value of $31.2 million through Dec 2025, up 70.23%, and an annual FY2025 reading of $31.2 million, up 70.23% over the prior year.
  • Change in Accured Expenses was $12.7 million for Q4 2025 at Esperion Therapeutics, down from $21.2 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $25.0 million in Q1 2021 and bottomed at -$21.8 million in Q2 2021.
  • Average Change in Accured Expenses over 5 years is $4.1 million, with a median of $2.8 million recorded in 2021.
  • The sharpest move saw Change in Accured Expenses plummeted 394.93% in 2021, then surged 690.34% in 2023.
  • Year by year, Change in Accured Expenses stood at -$789000.0 in 2021, then surged by 255.77% to $1.2 million in 2022, then surged by 566.8% to $8.2 million in 2023, then fell by 22.55% to $6.3 million in 2024, then surged by 100.41% to $12.7 million in 2025.
  • Business Quant data shows Change in Accured Expenses for ESPR at $12.7 million in Q4 2025, $21.2 million in Q3 2025, and -$1.7 million in Q2 2025.